The Israeli pharmaceutical company Oravax Medical, specializing in the development of drugs that are administered orally, will launch the final phase of clinical trials to test its pill against the disease of Covid-19, an alternative that could boost the campaigns of immunization globally starting next year.

The company received the endorsement by the review board of the Ichilov Hospital, the main hospital in Tel Aviv (Israel) to advance clinical studies, although the company reported that the date for the pill to be available in the market for its massive consumption will not be before 2022.

“Oravax is preparing to begin clinical trials of its oral covid-19 vaccine, the first in Israel, and then at additional clinical sites internationally. The study protocol has been approved by the Institutional Review Board (IRB) of the Ichilov Hospital in Tel Aviv, Israel, and is now pending approval from the Israeli Ministry of Health ”, they pointed out from the pharmaceutical company on its website .

The pill against the coronavirus does not require needles for its application and neither does it need to be stored at the ultra-cold temperatures required by injections developed by other pharmaceutical companies, such as Pfizer and Moderna, for example.

“Our vaccine is a particularly strong candidate [sic] against the evolving covid-19 virus, due to its unique target of three proteins instead of one. Since delta and other variants represent a challenge for healthcare managers globally, Oravax VLP technology could prove even more important in the effort to combat COVID, ” explained Nadav Kidron, CEO of Oramed, the company that owns Oravax Medical. Inc.

The first clinical trial is expected to include the participation of 24 volunteers who have not been vaccinated against the coronavirus so far. Each of the volunteers will take one or two pills of the oral vaccine.

From this procedure, the experts will analyze the safety of the vaccine and the immunity indicators it provides. Later, more advanced phase clinical trials will be conducted, with a larger sample of participants.

Other pharmaceutical companies such as Pfizer and Merck also announced several months ago that they are conducting trials of pills to treat COVID-19.

The Japanese company Shionogi announced that it has begun to test a pill against covid-19 in humans with the aim of analyzing its effectiveness and possible side effects, joining other pharmaceutical companies globally that are working to develop an oral treatment against the virus.

The main benefit that this type of pill would bring is that it would allow to neutralize the coronavirus in less than a week through a dosage of one capsule a day. The company reported that the tests will probably last until next year, as reported in an article in the American newspaper The Wall Street Journal .

“Our goal is a very safe oral compound, such as Tamiflu or Xofluza (drugs indicated for the flu),” Isao Teshirogi, CEO of Shionogi, told the American newspaper.